- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05026697
Validity and Reliability of Commercially Available Bioelectrical Impedance Analysis Devices (CBIA)
Study Overview
Status
Conditions
Detailed Description
The purpose of this data collection is to establish the validity and reliability of several different commercially available bioelectrical impedance analysis devices that are used to estimate body composition.
This study will involve 1-2 total visits: one initial visit followed by an optional follow-up visit 12-16 weeks later. These visits will consist of body composition assessments after an overnight fast. Before the overnight fast, the individual will be asked to drink 1 liter (the equivalent of two 16.9-ounce water bottles) between the final meal of the day and the beginning of the 8-hour fasting period. At the first visit, participants will undergo dual x-ray absorptiometry (DXA; GE Lunar Prodigy), air displacement plethysmography (ADP; Cosmed Bod Pod), a 3D body scan (SizeStream SS20), and several multi- and single-frequency bioelectrical impedance analysis (BIA) assessments. The BIA assessment methods will be conducted twice. This will allow for test-retest reliability assessment of each of the BIA devices being assessed in our study. At the optional second visit, all assessment methods utilized in our laboratory will be conducted once. By comparing these values to the values from the first visit, we will be able to establish the cumulative error due to technical error and biological error (i.e. random biological differences in the participants between the two assessments). We will collect data in a similar fashion during this second visit in order to compare the changes over time between the measurements provided by the commercially available BIA devices against the changes detected by a validated 4-compartment model of body composition, which uses research-grade devices. Cumulatively, this information will provide essential data to consumers regarding both the immediate and long-term test-retest reliability as well as the validity of commercially available BIA devices such as home body fat scales.
The commercially available BIA devices being examined in the present study includes:
- Omron HBF-306
- RENPHO Smart Bathroom Scale (item number: ES-26BB-B)
- Hawanna Body Fat Scale (UPC: 791555289926)
- Wyze Scale (SKU: WHSCL1)
- INEVIFIT Smart Body Fat Scale (UPC: 711841680565; EAN: 0711841680565)
- WeightWatchers Scale by Conair (model: WW721XF)
- Tanita UM-081 (model: UM-081; EAN: 0742496801012 and 0885157966993)
- VitaGoods FormFit Digital Scale and Body Analyzer (model: VG42252-0000)
- Omron HBF 516 Body Composition Monitor (model: HBF-516B)
- Seca sensa 804
- Withings/Nokia BodyCardio Body Composition Digital Scale (model: WBS04b-Black-All-Inter)
- Tanita BC554 IronMan Body Composition Monitor (model: BC-554)
- Tanita BC568 InnerScan Segmental Body Composition Monitor (model: BC-568)
- InBody H2ON Smart Full Body Composition Analyzer
Additionally, several laboratory-grade bioimpedance technologies will be performed, including ImpediMed SFB7 bioimpedance spectroscopy and Seca mBCA 515/514 multi-frequency bioelectrical impedance analysis. Urine specific gravity will also be assessed using digital refractometry, and height will be assessed via stadiometer. As part of the ADP test, body mass estimates from a calibrated, research-grade scale will be obtained (Modified BWB-627-A, Tanita Corporation).
The test-retest reliability of the commercially available bioelectrical impedance analysis devices will be examined through duplicate assessments. The validity of the commercially available bioelectrical impedance analysis devices will be examined as compared to the criterion laboratory methods, namely the 4-compartment model for total body composition and DXA and/or laboratory-grade segmental bioimpedance technologies for segmental body composition.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79409
- Department of Kinesiology & Sport Management
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Between the ages of 18 and 50
- Generally healthy (defined as an absence of any disease or medical condition which could potentially result in abnormal body composition, including but not limited to musculoskeletal or metabolic diseases)
- Weight-stable (defined as no change in body mass >5 pounds in the past month)
Exclusion Criteria:
- Failing to meet any of the aforementioned inclusion criteria or self-reporting a body composition abnormality (due to medical condition, lifestyle practices, etc.)
- Height greater than 75.5 inches (due to height limitation of DXA scanner)
- Weight greater than 330 pounds (due to weight limitation of some of the devices used)
- Presence of facial hair longer than 1/2 inch (and unwillingness to shave) or self-report of large amounts of body hair due to the impact of hair on Bod Pod body volume estimates
- Presence of pacemaker or any electrical device (due to electrical currents administered by bioimpedance devices)
- Amputation of limb, implantation of a meaningful amount metal (e.g., full joint replacement), or physical deformity large enough to invalidate traditional body composition assessments
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body fat percentage
Time Frame: 1 day
|
Percentage of body mass that is attributable to fat mass.
This value is provided by each body composition assessment device being tested (see list of devices in Study Description).
|
1 day
|
|
Fat-free mass
Time Frame: 1 day
|
Calculated as body mass minus fat mass.
Fat mass is equal to body mass multiplied by body fat percentage.
Body fat percentage is provided by each body composition assessment device being tested (see list of devices in Study Description).
|
1 day
|
|
Fat mass
Time Frame: 1 day
|
Body mass multiplied by body fat percentage.
Body fat percentage is provided by each body composition assessment device being tested (see list of devices in Study Description).
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Segmental body fat percentage
Time Frame: 1 day
|
Body fat percentage provided for specific body segments (i.e., trunk/torso, arms, and legs).
These values are provided by some, but not all, of the body composition assessment devices being tested (see list of devices in Study Description).
|
1 day
|
|
Segmental fat-free mass
Time Frame: 1 day
|
Fat-free mass (i.e., body mass minus fat mass) provided for specific body segments (i.e., trunk/torso, arms, and legs).
These values are provided by some, but not all, of the body composition assessment devices being tested (see list of devices in Study Description).
|
1 day
|
|
Segmental fat mass
Time Frame: 1 day
|
Fat mass provided for specific body segments (i.e., trunk/torso, arms, and legs).
These values are provided by some, but not all, of the body composition assessment devices being tested (see list of devices in Study Description).
|
1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body mass
Time Frame: 1 day
|
Body mass estimates provided by the scale of each body composition assessment device (see list of devices in Study Description).
|
1 day
|
|
Total body water
Time Frame: 1 day
|
Mass of total body water.
These values are provided by some, but not all, of the body composition assessment devices being tested (see list of devices in Study Description).
|
1 day
|
|
Visceral fat
Time Frame: 1 day
|
Mass of visceral fat.
These values are provided by some, but not all, of the body composition assessment devices being tested (see list of devices in Study Description).
|
1 day
|
|
Bone mineral mass
Time Frame: 1 day
|
Mass of bone mineral; These values are provided by some, but not all, of the body composition assessment devices being tested (see list of devices in Study Description).
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Grant Tinsley, PhD, Texas Tech University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB2021-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Composition
-
Efforia, IncRecruiting
-
Dynamical Business and Science Society - DBSS International...Universidad de Córdoba; CES University; ARTHROS Centro de Fisioterapia y EjercicioRecruiting
-
Nova Southeastern UniversityCompleted
-
Centro Universitario de Ciencias de la Salud, MexicoCompleted
-
University of Southern CaliforniaCompleted
-
University of California, San FranciscoHologic, Inc.Completed
-
University of SurreyUnknownBody Composition
-
Texas Woman's UniversityCompleted
-
Efforia, IncRecruiting
-
Efforia, IncRecruiting